CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-28
DOI
10.1038/s41375-023-02071-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma
- (2023) Hélène Asnagli et al. HemaSphere
- Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation
- (2023) Norbert Minet et al. Life Science Alliance
- Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells
- (2022) Zhe Sun et al. CANCER RESEARCH
- CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1
- (2022) Yuxiang Lin et al. Journal of Translational Medicine
- In silico recognition of a prognostic signature in basal-like breast cancer patients
- (2022) Federica Conte et al. PLoS One
- CTP sensing and Mec1ATR-Rad53CHK1/CHK2 mediate a two-layered response to inhibition of glutamine metabolism
- (2022) Arta Ajazi et al. PLoS Genetics
- A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma
- (2021) Han-ying Huang et al. LEUKEMIA
- DHODH and cancer: promising prospects to be explored
- (2021) Yue Zhou et al. Cancer & Metabolism
- Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma
- (2021) Saurabh Zanwar et al. LEUKEMIA & LYMPHOMA
- Cell cycle control in cancer
- (2021) Helen K. Matthews et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural basis for isoform-specific inhibition of human CTPS1
- (2021) Eric M. Lynch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies
- (2019) Oronza A. Botrugno et al. HAEMATOLOGICA
- Towards personalized treatment in multiple myeloma based on molecular characteristics
- (2018) Charlotte Pawlyn et al. BLOOD
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
- (2017) Ana Belén Herrero et al. Frontiers in Oncology
- Clinical value of molecular subtyping multiple myeloma using gene expression profiling
- (2015) N Weinhold et al. LEUKEMIA
- Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
- (2015) F. Cottini et al. Cancer Discovery
- Targeting the bone marrow microenvironment in multiple myeloma
- (2014) Yawara Kawano et al. IMMUNOLOGICAL REVIEWS
- CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation
- (2014) Emmanuel Martin et al. NATURE
- Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
- (2014) Francesca Cottini et al. NATURE MEDICINE
- Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX
- (2011) D K Walters et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
- (2010) A. Broyl et al. BLOOD
- A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect
- (2009) Luca Agnelli et al. GENES CHROMOSOMES & CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started